Anakinra also is for used for treatment of neonatal-onset multisystem inflammatory disease (NOMID) due to cryopyrin-associated periodic syndromes (CAPS).
SIDE EFFECTS: The most common side effects are reactions at the site of injection, for example, redness, swelling and pain.
Other minor side effects include:
The most serious side effects are an increase in infections and a decrease in the number of white blood cells (neutropenia) and platelets.
Anakinra should not be started in individuals with active infections.
Infections occur more frequently when anakinra is used in combination with drugs that block tumor necrosis factor.
GENERIC AVAILABLE: No
PREPARATIONS: Pre-filled syringes, 100 mg
STORAGE: Anakinra should be kept refrigerated at 2 C to 8 C (36 F to 46 F)
- The dose of anakinra for rheumatoid arthritis is one subcutaneous injection of 100 mg daily. The dose should be administered at approximately the same time every day.
- The dose for treating neonatal-onset multisystem inflammatory disease (NOMID) is 1-2 mg/kg daily up to a maximum dose of 8 mg/kg.
DRUG INTERACTIONS: Anakinra should not be combined with drugs that block tumor necrosis factor (TNF) alpha. Combining anakinra with drugs that block tumor necrosis factor such as infliximab (Enbrel) and etanercept (Remicade) or other drugs that reduce function of the immune system increases the risk of serious infections.
PREGNANCY: Anakinra has not been studied in pregnant women.
NURSING MOTHERS: It is not known if anakinra is excreted in the breast milk of females who are nursing.
Reference: FDA Prescribing Information
Quick GuideRheumatoid Arthritis Symptoms and Treatment
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.